Regulating hematology/oncology research involving human participants.
The conduct of hematology/oncology research, particularly clinical trials involving human participants, is an extensively regulated enterprise. Professionals in the specialty of hematology/oncology have important stakes in the success of biomedical research endeavors. Knowledge about and compliance strategies regarding the pertinent regulatory parameters are essential for avoiding negative legal repercussions for involved professionals. At the same time, there is a need to be aware of and actively resist the danger that strong [legal] protectionism might inadvertently result in undermining physician investigators' sense of personal moral responsibility in the conduct of human experiments. For all the limitations of that virtue in the protection of human subjects, it is surely not one that we would want medical scientists to be without [47]. Members of the potential participant pool, financial sponsors, and the general public must be convinced that everyone involved in the research enterprise is committed to operating within acceptable legal and ethical boundaries if the atmosphere of confidence and trust that is indispensable to the continued process and progress of investigation aimed at extending and improving quality of life for all of us in the future is to continue and flourish [48].
Kapp
Marshall B
MB
Office of Geriatric Medicine and Gerontology, Wright State University School of Medicine, University of Dayton School of Law, Dayton, OH, USA. marshall.kapp@wright.edu
D003582:Cytogenetics / Q000331:legislation & jurisprudence; D006405:Hematology / Q000331:legislation & jurisprudence*; D006805:Human Experimentation / Q000331:legislation & jurisprudence*; D006801:Humans; D008495:Medical Oncology / Q000331:legislation & jurisprudence*; D016032:Randomized Controlled Trials as Topic / Q000331:legislation & jurisprudence; D012106:Research / Q000331:legislation & jurisprudence*; D012306:Risk